Tag: US15102K1007

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsUS15102K1007

Remittix Confirms Q3 2025 Beta Wallet Launch with Solana and Ethereum Support, Presale Surpasses $17.3 Million

Remittix Announces Q3 2025 Beta Wallet Launch with Solana Network Support, Raising Over $17.3 Million in Ongoing Presale

No KYC. 100x Leverage. Double Deposit Bonus Match. Crypto Futures Trading Made Easy on BexBack.

Tag: US15102K1007

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us